ProMis Neurosciences, Inc
ProMIS Neurosciences is a clinical-stage biotechnology company dedicated to discovering and developing therapeutic antibodies that target toxic oligomers associated with neurodegenerative and misfolded protein diseases, including Alzheimer’s disease, ALS, FTD, MSA, and Parkinson’s Disease. The company leverages proprietary technology, EpiSelect™, and computational modeling to create highly selective therapeutic antibodies, vaccines, and diagnostics. With offices in Toronto, Canada, and Cambridge, Massachusetts, ProMIS aims to improve clinical outcomes by targeting the biological causes of these diseases.
Industries
Nr. of Employees
small (1-50)
ProMis Neurosciences, Inc
1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2, Canada
Patents
Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
US-12071472-B2
View Details
Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
US-12071472-B2
View DetailsProducts
Selective antibody therapeutic candidates targeting toxic misfolded oligomers
Pipeline of therapeutic monoclonal antibodies designed to selectively bind toxic oligomeric conformations of disease-associated proteins for neurodegenerative indications.
Vaccine candidates derived from epitope-prediction platform
Vaccine program candidates designed against conformational epitopes of misfolded proteins identified by computational prediction.
Diagnostic assay candidates for misfolded protein detection
Diagnostic development efforts focused on assays that detect disease-specific conformational epitopes or related fluid biomarkers for neurodegenerative diseases.
Early-phase intravenous antibody clinical candidate
Intravenous monoclonal antibody candidate undergoing Phase 1b multiple-ascending dose testing to evaluate safety, tolerability, PK/PD and preliminary efficacy in early-stage neurodegenerative disease.
Selective antibody therapeutic candidates targeting toxic misfolded oligomers
Pipeline of therapeutic monoclonal antibodies designed to selectively bind toxic oligomeric conformations of disease-associated proteins for neurodegenerative indications.
Vaccine candidates derived from epitope-prediction platform
Vaccine program candidates designed against conformational epitopes of misfolded proteins identified by computational prediction.
Diagnostic assay candidates for misfolded protein detection
Diagnostic development efforts focused on assays that detect disease-specific conformational epitopes or related fluid biomarkers for neurodegenerative diseases.
Early-phase intravenous antibody clinical candidate
Intravenous monoclonal antibody candidate undergoing Phase 1b multiple-ascending dose testing to evaluate safety, tolerability, PK/PD and preliminary efficacy in early-stage neurodegenerative disease.
Services
Consulting services covering regulatory affairs, chemistry, manufacturing and controls (CMC), preformulation, formulation, analytical development, and clinical supply management for peptide and protein therapeutics.
Design, sponsor oversight and operational management of Phase 1b randomized, double-blind, placebo-controlled, multiple-ascending dose trials including PK/PD and safety assessments.
Provision of computational modeling and bioinformatics workflows to predict disease-specific epitopes on misfolded proteins to guide antibody and vaccine design.
Preparation and publication of periodic SEC filings, proxy materials and investor communications, and distribution of press releases and financial reports.
Consulting services covering regulatory affairs, chemistry, manufacturing and controls (CMC), preformulation, formulation, analytical development, and clinical supply management for peptide and protein therapeutics.
Design, sponsor oversight and operational management of Phase 1b randomized, double-blind, placebo-controlled, multiple-ascending dose trials including PK/PD and safety assessments.
Provision of computational modeling and bioinformatics workflows to predict disease-specific epitopes on misfolded proteins to guide antibody and vaccine design.
Preparation and publication of periodic SEC filings, proxy materials and investor communications, and distribution of press releases and financial reports.
Expertise Areas
- Therapeutic antibody development targeting misfolded protein conformers
- Vaccine and diagnostic development for conformational epitopes
- Protein misfolding and prion-like mechanism research
- Computational target discovery and epitope prediction
Key Technologies
- Epitope prediction algorithms
- Molecular dynamics simulations
- Machine learning for protein target selection
- Antibody engineering and discovery platforms